(2S,3S,5R)-4-azido-2-[(2S,3R,5R)-4-azido-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2S,3S,5R)-4-azido-2-[(2S,3R,5R)-4-azido-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]sulfanyl-6-(hydroxymethyl)oxane-3,5-diol
• 化学式: C12H20N6O8S
• 分子量: 408.39
• InChiKey: AZZIBGKZSLGNAF-YUTKGBEVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  27
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  194
• 氢给体数：
  6
• 氢受体数：
  13

文献信息

• Novel galactoside inhibitor of galectins
  申请人：GALECTO BIOTECH AB

  公开号：US20160096861A1

  公开（公告）日：2016-04-07

  Provided is a compound of the general formula (I): The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Also provided is a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject having a galectin-3 level indicative of pulmonary fibrosis or exacerbation of symptoms as well as a method for making said compound.

  提供的是通式（I）的化合物：公式（I）的化合物适用于治疗哺乳动物的肺纤维化，如特发性肺纤维化。还提供了一种治疗肺纤维化的方法，例如对于人类患有表明肺纤维化或症状加剧的半乳糖凝集素-3水平的特发性肺纤维化患者，以及制备该化合物的方法。
• NOVEL SYNTHESIS OF GALACTOSIDE INHIBITORS
  申请人：GALECTO BIOTECH AB

  公开号：US20140171630A1

  公开（公告）日：2014-06-19

  Novel synthesis routes for preparation of thiodigalactosides and intermediates are presented. The method includes the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corresponding thiol in situ, which in turn is directly reacted with a 3-azido-galactosyl bromide resulting in the 3,3′-di-azido-thio-di-galactoside before the thiol has a chance to reduce the azido 10 group. Hence, in situ formation of the 3-azido-galactosyl thiol from the thiouronium salt is essential in the synthesis procedure, because any other method that generate the thiol separately results in extensive unwanted azide reduction.

  本文介绍了制备硫代半乳糖苷和中间体的新型合成路线。该方法包括使用3-偶氮基-半乳糖基硫脲盐衍生物，该衍生物在原位被激活成相应的巯基，巯基直接与3-偶氮基-半乳糖基溴反应，形成3,3'-二偶氮基硫代二半乳糖苷，此时巯基还没有机会还原偶氮基。因此，在合成过程中原位形成3-偶氮基-半乳糖基巯基是必要的，因为任何其他单独生成巯基的方法都会导致大量不必要的偶氮基还原。
• Methods, compositions and kits for treating, modulating, or preventing ocular angiogenesis or fibrosis in a subject using a galectin protein inhibitor
  申请人：TUFTS UNIVERSITY

  公开号：US20150320782A1

  公开（公告）日：2015-11-12

  Methods and kits using a pharmaceutical composition for use in inhibiting ocular angiogenesis or fibrosis are provided herein, such that composition includes a pharmaceutically suitable carrier or diluent and an amount of the inhibitor composition effective to inhibit the angiogenesis or the fibrosis by inhibiting expression and/or activity of a galectin protein or a portion thereof.
• GALACTOSIDE INHIBITORS FOR NEW USES
  申请人：GALECTO BIOTECH AB

  公开号：US20170095496A1

  公开（公告）日：2017-04-06

  Provided is a method for treatment or prevention of α-synucleinopathies in a mammalian subject, the method comprising administering a therapeutically effective amount of at least one composition to the subject, wherein the composition comprises a molecule for pharmacological modulation of galectin activity in a mammalian brain.
• US9688713B2
  申请人：——

  公开号：US9688713B2

  公开（公告）日：2017-06-27